Pheast Therapeutics is using a platform-based approach to scaling manufacturing for its anti-CD24 checkpoint inhibitor, PHST001. By compressing the chemistry, manufacturing, and control (CMC) steps ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback